Core Insights - Huyou Pharmaceutical's stock closed at 21.45 yuan, down 3.81%, currently in a state of decline since its IPO [1] - The company went public on October 26, 2021, on the Sci-Tech Innovation Board, issuing 63.6 million shares at a price of 38.87 yuan per share [1][2] - The total funds raised amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, exceeding the initial plan by 453 million yuan [2] Financial Performance - From 2021 to 2023, the company's revenue was 1.824 billion yuan, 1.493 billion yuan, and 927 million yuan respectively, with net profits of 446 million yuan, 249 million yuan, and 140 million yuan [3] - In 2024, the company projected revenue of 1.094 billion yuan, an increase of 18.05%, with net profit expected to reach 325 million yuan, a growth of 132.78% [3] - For the first half of 2025, the company reported revenue of 453 million yuan, a decrease of 14.86%, and a net loss of 80.72 million yuan [4]